Rahul D. Ballal, Ph.D.

Rahul D. Ballal, Ph.D.

DirectoratEnliven Therapeutics· In proxies 2022–2025

Pay in FY2023+62% from the year before · Enliven Therapeutics stock -15.4% the same year

Rahul D. Ballal, Ph.D. was paid $1.9M in FY2023 (Dec), up 62%. Enliven Therapeutics stock fell 15.4% that year.

Pay$100 in the stock at the end of FY21 → $154
Pay is from the Summary Compensation Table of each Enliven Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Agios PharmaceuticalsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Enliven TherapeuticsPublic company · 4 yr
    • Director2022 – Present · 4 yrStock in role +357%
  3. Attralus, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Vaderis Therapeutics AGPublic company
    • Director? – PresentNo stock prices for these years
  5. Phoenix Tissue Repair, Inc.Public company · 4 yr
    • Director2018 – 2022 · 4 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?